Pre-Made Eflimrufusp Alfa Biosimilar, Fusion Protein targeting FGF2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BFGF/FGF-2/FGFB/HBGF-2 for drug discovery and mechanism of action (MOA) research

Pre-Made Eflimrufusp Alfa Biosimilar, Fusion Protein targeting FGF2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BFGF/FGF-2/FGFB/HBGF-2 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) play important roles in angiogenesis-related diseases. Eflimrufusp alfa is a soluble fusion protein composed of the human VEGF receptor 1 (VEGFR1) extracellular domain 2 (ECD 2), VEGFR2 ECD 3, FGFR1 ECDs 2 and 3, and the Fc regions of human immunoglobulin G1. By targeting VEGF and FGF2, RC28-E may represent a useful antiangiogenetic agent.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-820-1mg	1mg	3090
GMP-Bios-INN-820-10mg	10mg	Inquiry
GMP-Bios-INN-820-100mg	100mg	Inquiry
GMP-Bios-INN-820-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Eflimrufusp Alfa Biosimilar, Fusion Protein targeting FGF2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BFGF/FGF-2/FGFB/HBGF-2
INN Name	Eflimrufusp Alfa
Target	FGF2
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	Fusion - [FLT1 (fms- related tyrosine kinase 1, vascular endothelial growth factor receptor 1, VEGFR-1, VEGFR, FLT, FRT, vascular permeability factor receptor) domain 2 fragment (132-232) - KDR (kinase insert domain receptor, vascular endothelial growth factor receptor 2, VEGFR2, VEGF- R2, FLK1, CD309) domain 3 fragment (227-327) - FGFR1 (fibroblast growth factor receptor 1, FLT2, KAL2) domains 2 and 3 fragment (150- 361)]2 - IGHG1 Fc (Fragment constant)
VD LC	Fusion - [FLT1 (fms- related tyrosine kinase 1, vascular endothelial growth factor receptor 1, VEGFR-1, VEGFR, FLT, FRT, vascular permeability factor receptor) domain 2 fragment (132-232) - KDR (kinase insert domain receptor, vascular endothelial growth factor receptor 2, VEGFR2, VEGF- R2, FLK1, CD309) domain 3 fragment (227-327) - FGFR1 (fibroblast growth factor receptor 1, FLT2, KAL2) domains 2 and 3 fragment (150- 361)]2 - IGHG1 Fc (Fragment constant)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	RemeGen, Ltd. (Shandong China)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0